“…Therefore, the use of miRNAs as engineering tools can be challenging, but offers the opportunity to control entire cellular pathways without any energy‐consuming translational burden [ 15 ]. Therefore, miRNA‐associated engineering approaches were established as efficient tools in CHO cell line engineering for the improvement of productivity, fine‐tuning of product quality, the enhancement of cell growth and survival, and the modulation of metabolic pathways [ 3 , 6 , 8 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. However, quality‐relevant characteristics of therapeutic proteins like antibody fucosylation have so far been engineered using standard techniques like knock‐out of genes [ 5 , 31 , 32 , 33 , 34 ], siRNA mediated transient gene knock‐down [ 27 , 35 , 36 ] or miRNA‐mediated transient gene knock‐down [ 37 ] only.…”